Proceeds will be used to grow the commercial organization, scale-up manufacturing operations, and launch additional products in the R&D pipeline.

SAN DIEGO, June 10, 2025 /PRNewswire/ — Atraverse Medical, a medical device company pioneering next-generation transseptal access technology, today announced the close of a $29.4 million follow-on financing to accelerate growth. The raise builds upon $12.5 million in prior seed investment that was used to obtain FDA 510(k) clearance and begin early commercialization of HOTWIRE™, the company’s novel radiofrequency (RF) guidewire for left-heart access. The company has now raised over $40 million of investment capital. 

Designed to simplify left-heart access through universal sheath compatibility and a zero-exchange workflow, and engineered for enhanced echogenicity and increased rail stiffness, HOTWIRE™ is the focus of the company’s current U.S. commercialization strategy.

“This financing is a major milestone for Atraverse and underscores our evolution from a startup company to an emerging growth corporation,” commented John Slump, CEO/President and Co-Founder of Atraverse Medical. “We’re scaling manufacturing, expanding our team, and investing in new product development to build on the HOTWIRE™ platform. Our investor syndicate includes angel investors, family offices, and medtech entrepreneurs who share our conviction that HOTWIRE™ is setting a new standard as the future of left-heart access.”

“The most transformative medical technologies don’t just improve procedures—they reimagine entire categories,” said Jean-Luc Pageard, a seasoned entrepreneur, investor, and pioneering innovator of cryoballoon ablation, PFA and other groundbreaking technologies in the electrophysiology and cardiology arena. “HOTWIRE™ is redefining how physicians approach left-heart access. I invested in Atraverse because the company is developing a scalable, category-shaping innovation that is likely to become the new standard of care for left-heart access.”

“HOTWIRE™ delivers clinically significant advantages over existing left-heart access devices, and we are excited to be an early adopter and commercial customer,” commented Dr. Vivek Y. Reddy, Director of Cardiac Arrhythmia Services at Mount Sinai Hospital, New York, and co-author on studies regarding the clinical experience of HOTWIRE™.

Cleared by the FDA in May 2024, HOTWIRE™ is approaching its first 1,000 successful procedures across 10 different introducer sheaths as part of a limited market release. The device enables zero-exchange left-heart access and serves as a rail for catheter-based therapies. With universal sheath compatibility, HOTWIRE™ is designed to advance transseptal access technology, optimize procedural workflows, and support improved patient outcomes with a best-in-class platform for left-heart access.

ABOUT ATRAVERSE MEDICAL
Atraverse Medical is a medical device company pioneering next-generation left-heart access and optimized RF technology. The company’s proprietary HOTWIRE™ system, featuring universal sheath compatibility, aims to enhance outcomes and streamline workflows for physicians treating cardiovascular disease in millions of patients worldwide. Based in San Diego, CA, Atraverse was formed in July 2022 by Dr. Steven Mickelsen, John Slump, and Eric Sauter, the same founding team that created FARAPULSE (acquired in June 2021). For more information, visit www.atraversemedical.com.

SOURCE Atraverse Medical

Copyright © 2025 Cision US Inc.